Lawson Kroeker Investment Management Inc. NE Increases Stake in Johnson & Johnson (NYSE:JNJ)

Lawson Kroeker Investment Management Inc. NE grew its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 0.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 62,590 shares of the company’s stock after purchasing an additional 123 shares during the quarter. Johnson & Johnson makes up about 3.5% of Lawson Kroeker Investment Management Inc. NE’s investment portfolio, making the stock its 10th largest position. Lawson Kroeker Investment Management Inc. NE’s holdings in Johnson & Johnson were worth $11,093,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Family CFO Inc purchased a new stake in Johnson & Johnson during the 4th quarter valued at about $26,000. Steward Financial Group LLC purchased a new stake in Johnson & Johnson during the 4th quarter valued at about $34,000. Jackson Wealth Management LLC grew its position in shares of Johnson & Johnson by 1.7% in the 3rd quarter. Jackson Wealth Management LLC now owns 16,959 shares of the company’s stock worth $40,000 after buying an additional 277 shares during the last quarter. Advocacy Wealth Management Services LLC raised its holdings in shares of Johnson & Johnson by 41.4% during the first quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after acquiring an additional 67 shares in the last quarter. Finally, Iron Horse Wealth Management LLC lifted its stake in Johnson & Johnson by 29.9% in the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock worth $45,000 after acquiring an additional 61 shares during the period. Hedge funds and other institutional investors own 68.78% of the company’s stock.

NYSE:JNJ opened at $175.74 on Thursday. The firm’s 50-day moving average price is $177.66 and its 200-day moving average price is $173.09. The company has a market capitalization of $462.44 billion, a PE ratio of 23.68, a P/E/G ratio of 3.35 and a beta of 0.66. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last announced its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 EPS for the quarter, beating the consensus estimate of $2.60 by $0.07. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The company had revenue of $23.43 billion for the quarter, compared to the consensus estimate of $23.62 billion. During the same period in the prior year, the firm posted $2.59 EPS. Johnson & Johnson’s revenue for the quarter was up 5.0% on a year-over-year basis. Equities analysts anticipate that Johnson & Johnson will post 10.23 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th were given a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.57%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.06. The ex-dividend date of this dividend was Monday, May 23rd. Johnson & Johnson’s dividend payout ratio is 60.92%.

Several brokerages have commented on JNJ. Credit Suisse Group upped their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Sanford C. Bernstein lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and upped their price objective for the stock from $180.00 to $183.00 in a report on Wednesday, March 16th. Raymond James upped their price objective on shares of Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Citigroup decreased their price objective on shares of Johnson & Johnson from $210.00 to $205.00 in a report on Tuesday, May 17th. Finally, Daiwa Capital Markets began coverage on shares of Johnson & Johnson in a report on Wednesday. They issued an “outperform” rating for the company. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $190.50.

In other news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,785,140. The disclosure for this sale can be found here. Insiders have sold a total of 78,161 shares of company stock worth $13,895,302 over the last three months. 0.35% of the stock is currently owned by insiders.

Johnson & Johnson Profile (Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.